NEW CIS-IMIDAZOLINES Russian patent published in 2011 - IPC C07D403/06 C07D401/14 C07D413/14 A61K31/496 A61K31/4523 A61K31/5377 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to compounds of formula I and its pharmaceutically acceptable salts. In formula (I) , R stands for 6-unit ring, containing one ore two heteroatoms of nitrogen, and substituted with group selected from the following groups: (lower)alkyl, -C(O)-R₁, (lower)alkyl, substituted with group -SO₂-(lower)alkyl, (lower)alkyl, substituted with group -C(O)-R₁, -SO₂-(lower)alkyl, or 5-unit saturated ring, containing one heteroatom of nitrogen, R₁ is selected from group, including (lower)alkyl, -N((lower)alkyl)₂, or R₁ stands for 6-unit saturated ring, containing two heteroatoms, selected from N and O, X₁ and X₂ are independently selected from group, including hydrogen, (lower)alkoxy, each Y₁ and Y₂ are independently selected from group, including -Cl and -Br, and absolute stoichiometric configuration in position 4 and 5 imidazoline ring includes S and R configuration, accordingly. Invention also relates to pharmaceutical composition, having inhibiting activity regarding interaction of MDM2 - p-53, containing efficient amount of invention compound.

EFFECT: production of compounds, having inhibiting activity as regards interaction of MDM2-p-53.

12 cl, 17 ex